Skip to Main Content

Paper Details

A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma.
Clin Cancer Res
9
2023
CD57, CD57+, CD57+ effector memory T, CD57+T cells, CD8, CD8 T, CD8 T cell, CTLA-4, MPM, MPM tumors, Malignant Pleural Mesothelioma, PD-L1, Patients, Treg, durvalumab, malignant pleural mesothelioma, patients, tremelimumab, tumor
Author NameAffiliation
Susan G HilsenbeckDan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine
Christopher I AmosInstitute for Clinical and Translational Research, Baylor College of Medicine
Christopher I AmosInstitute for Clinical and Translational Research, Baylor College of Medicine
  • 1 - 3

Datasets

Release 1.2